参考文献/References:
[1]El-Naggar AKCJ,Grandis JR,Takata T,et al.WHO classification of head and neck tumours[M].4th ed.Lyon:IARC,2017.[2]Nam SJ,Roh JL,Cho KJ,et al.Risk factors and survival associated with distant metastasis in patients with carcinoma of the salivary gland[J].Ann Surg Oncol,2016,23(13):4376-4383.[3]Rajasekaran K,Stubbs V,Chen J,et al.Mucoepidermoid carcinoma of the parotid gland:a National Cancer Database study[J].Am J Otolaryngol,2018,39(3):321-326.[4]Chen MM,Roman SA,Sosa JA,et al.Histologic grade as prognostic indicator for mucoepidermoid carcinoma: apopulation-level analysis of 2400 patients[J].Head Neck,2014,36(2):158-163.[5]Seethala RR,Stenman G.Update from the 4th edition of the World Health Organization classification of head and neck tumours: tumors of thesalivary gland[J].Head Neck Pathol,2017,11(1):55-67.[6]Li S,Zhang Z,Tang H,et al.Pathological complete response to getinib in a 10-year-old boy with EGFR-negative pulmonary mucoepidermoid carcinoma:a case report and literature review[J].Clin Resp,2017,11(3):346-351.[7]Wong SJ,Karrison T,Hayes DN,et al.Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors[J].Eur Soc Med Oncol,2016,27(2):318-323.[8]支旺,温惠慧,崔志强.唾液腺腺样囊性癌组织中EGFR的表达及临床意义[J].长治医学院报,2017,31(2):98-100.[9]王蕊,李立恒,朱晓龙,等.涎腺腺样囊性癌中微血管密度与血管内皮生长因子的表达水平及临床意义[J].山西医药杂志,2017,46(22):2749-2751.[10]Agulnik M,Cohen EW,Cohen RB,et al.Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands[J].Am Soc Clin Oncol,2007,25(25):3978-3984.[11]Tchekmedyian V,Sherman EJ,Dunn L,et al.Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma[J].Am Soc Clin Oncol,2019,37(18):1529-1537.[12]Fujii K,Murase T,Beppu S,et al.MYB,MYBL1,MYBL2 and NFIB gene alterations and MYC overexpression in salivary gland adenoid cystic carcinoma[J].Histopathology,2017,71(5):823-834.[13]Andersson MK,Afshari MK,Andren Y,et al.Targeting the oncogenic transcriptional regulator MYB in adenoid cystic carcinoma by inhibition of IGF1R/AKT Signaling[J].Natl Cancer Inst,2017,109(9):10.[14]Ferrarotto R,Mitani Y,Diao L,et al.Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to notch1 inhibitors[J].Am Soc Clin Oncol,2017,35(3):352-360.[15]Ferrarotto R Eckhardt G,Patnaik A,et al.A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors[J].Eur Soc Med Oncol,2018,29(7):1561-1568.[16]Even C,Lassen U,Merchan J,et al.Safety and clinical activity of the Notch inhibitor,crenigacestat(LY3039478),in an openlabel phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma[J].Invest New Drugs,2019,38(2):402-409.[17]Ferdinandus J,Violet J,Sandhu S,et al.Prostate-specific membrane antigen theranostics:therapy with lutetium-177[J].Curr Opin Urol,2018,28(2):197-204.[18]Skalova A,Vanecek T,Martinek P,et al.Molecular profiling of mammary analog secretory carcinoma revealed a subset of tumors harboring a novel ETV6-RET translocation: report of 10 cases[J].Am J Surg Pathol,2018,42(2):234-246.[19]Cocco E,Scaltriti M,Drilon A.NTRK fusion-positive cancers and TRK inhibitor therapy[J].Nat Rev Clin Oncol,2018,15(12):731-747.[20]Biron VL,Lentsch EJ,Gerry DR,et al.Factors influencing survival in acinic cell carcinoma:a retrospective survival analysis of 2061 patients[J].Head Neck,2015,37(6):870-877.[21]Andreasen S,Varma S,Barasch N,et al.The HTN3-MSANTD3 fusion gene defines a subset of acinic cell carcinoma of the salivary gland[J].Am J Surg Pathol,2019,43(4):489-496.[22]Solomon JP,Linkov I,Rosado A,et al.NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls[J].Mod Pathol,2020,33(1):38-46.[23]Hernandez-Prera JC.Historical evolution of the polymorphous adenocarcinoma[J].Head Neck Pathol,2019,13(3):415-422.[24]Weinreb I,Piscuoglio S,Martelotto LG,et al.Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands[J].Nat Genet,2014,46(11):1166-1169.[25]Otsuka K,Imanishi Y,Tada Y,et al.Clinical outcomes and prognostic factors for salivary duct carcinoma:a multi-institutional analysis of 141 patients[J].Ann Surg Oncol,2016,23(6):2038-2045.[26]Boon E,BelM,vanBoxtel W,et al.A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands[J].Cancer,2018,143(4):758-766.[27]Takase S,Kano S,Tada Y,et al.Biomarker immunoprole in salivary duct carcinomas:clinicopathological and prognostic implications with evaluation of the revised classification[J].Oncotarget,2017,8(35):59023-59035.[28]Fushimi C,Tada Y,Takahashi H,et al.A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma[J].Eur Soc Med Oncol,2018,29(4):979-984.[29]van Boxtel W,Locati LD,van Engen-van Grunsven ACH,et al.Adjuvant androgen deprivation therapy for poor-risk,androgen receptor-positive salivary duct carcinoma[J].Eur J Cancer,2019(110):62-70.[30]Takahashi H,Tada Y,Saotome T,et al.Phase II trialoftrastuzumabanddocetaxel inpatients withhumanepidermalgrowthfactor receptor 2-positive salivary duct carcinoma[J].Am Soc Clin Oncol,2019,37(2):125-134.[31]Shimura T,Tada Y,Hirai H,et al.Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas[J].Oncotarget,2018,9(2):1852-1867.[32]Bjorndal K,Krogdahl A,Therkildsen MH,et al.Salivary gland carcinoma in Denmark 1990-2005:a national study of incidence,site and histology.Results of the Danish Head and Neck Cancer Group (DAHANCA)[J].Oral Oncol,2011,47(7):677-682.[33]Hu YH,Li W,Zhang CY,et al.Prognostic nomogram for disease-speciic survival of carcinoma ex pleomorphic adenoma of the salivary gland[J].Head Neck,2017,39(12):2416-2424.[34]Asahina M,Saito T,Hayashi T,et al.Clinicopathological effect of PLAG1 fusion genes in pleomorphic adenoma and carcinoma ex pleomorphic adenoma with special emphasis on histological features[J].Histopathology,2019,74(3):514525.
相似文献/References:
[1]袁东方,张刚刚.恶性肿瘤病历主要诊断选择思路分析[J].医学信息,2018,31(07):28.[doi:10.3969/j.issn.1006-1959.2018.07.010]
YUAN Dong-fang,ZHANG Gang-gang.Analysis of Main Diagnostic Options for Malignant Tumor Records[J].Medical Information,2018,31(13):28.[doi:10.3969/j.issn.1006-1959.2018.07.010]
[2]陶碧君,刘建德,王玉洲.LncRNA FOXD3-AS1在恶性肿瘤中的表达、功能及作用机制[J].医学信息,2022,35(10):51.[doi:10.3969/j.issn.1006-1959.2022.10.012]
TAO Bi-jun,LIU Jian-de,WANG Yu-zhou.Expression, Function and Mechanism of LncRNA FOXD3-AS1 in Malignant Tumors[J].Medical Information,2022,35(13):51.[doi:10.3969/j.issn.1006-1959.2022.10.012]
[3]张国锐,贾 林,赵 丹,等.老年维持血液透析患者恶性肿瘤发病的相关因素分析[J].医学信息,2022,35(10):113.[doi:10.3969/j.issn.1006-1959.2022.10.027]
ZHANG Guo-rui,JIA Lin,ZHAO Dan,et al.Analysis of Related Factors of Malignant Tumor in Elderly Maintenance Hemodialysis Patients[J].Medical Information,2022,35(13):113.[doi:10.3969/j.issn.1006-1959.2022.10.027]
[4]姜天奇,张洪亮.原发性肝癌的中西医治疗现状[J].医学信息,2019,32(13):35.[doi:10.3969/j.issn.1006-1959.2019.13.012]
JIANG Tian-qi,ZHANG Hong-liang.Current Status of Treatment of Primary Liver Cancer with Traditional Chinese Medicine and
Western Medicine[J].Medical Information,2019,32(13):35.[doi:10.3969/j.issn.1006-1959.2019.13.012]
[5]何 静.上皮性卵巢癌化学治疗的研究[J].医学信息,2019,32(18):24.[doi:10.3969/j.issn.1006-1959.2019.18.009]
HE Jing.Chemotherapy of Epithelial Ovarian Cancer[J].Medical Information,2019,32(13):24.[doi:10.3969/j.issn.1006-1959.2019.18.009]
[6]梁春玲,杨文珊.消化道恶性肿瘤的临床分析[J].医学信息,2019,32(18):124.[doi:10.3969/j.issn.1006-1959.2019.18.041]
LIANG Chun-ling,YANG Wen-shan.Clinical Analysis of Malignant Tumors of the Digestive Tract[J].Medical Information,2019,32(13):124.[doi:10.3969/j.issn.1006-1959.2019.18.041]
[7]陈云娥,李 璠,张子怡,等.营养支持治疗对终末期恶性肿瘤患者临床结局影响的Meta分析[J].医学信息,2019,32(19):63.[doi:10.3969/j.issn.1006-1959.2019.19.019]
CHEN Yun-e,LI Fan,ZHANG Zi-yi,et al.Meta-analysis of Effect of Nutritional Support Therapy on Clinical Outcome of Patients with Terminal-stage Malignant Tumor[J].Medical Information,2019,32(13):63.[doi:10.3969/j.issn.1006-1959.2019.19.019]
[8]杜鑫荣.超声造影在肝实质性肿块诊断及鉴别中的临床价值[J].医学信息,2019,32(19):176.[doi:10.3969/j.issn.1006-1959.2019.19.059]
DU Xin-rong.Clinical Value of Contrast-enhanced Ultrasonography in the Diagnosis and Differential Diagnosis of Liver Mass[J].Medical Information,2019,32(13):176.[doi:10.3969/j.issn.1006-1959.2019.19.059]
[9]易亭伍,邓窈窕,宿向东.恶性肿瘤患者及家属信息需求现状的多中心研究[J].医学信息,2019,32(22):72.[doi:10.3969/j.issn.1006-1959.2019.22.023]
YI Ting-wu,DENG Yao-tiao,SU Xiang-dong.Multi-center Study on the Status of Information Needs of Patients with Malignant Tumors and their Families[J].Medical Information,2019,32(13):72.[doi:10.3969/j.issn.1006-1959.2019.22.023]
[10]赵博志,赵国林,杨 敏,等.乳腺鳞状细胞癌的临床诊疗研究[J].医学信息,2020,33(03):46.[doi:10.3969/j.issn.1006-1959.2020.03.014]
ZHAO Bo-zhi,ZHAO Guo-lin,YANG Min,et al.Clinical Diagnosis and Treatment of Squamous Cell Carcinoma of the Breast[J].Medical Information,2020,33(13):46.[doi:10.3969/j.issn.1006-1959.2020.03.014]